Nanotechnology of emerging targeting systems

Minerva Biotecnologica

Volumn 20, Issue 3, 2008, Pages 127-131

  Smith, S S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Dendrimers; Nanoparticles; Nanotechnology; Nucleosome assembly protein 1

Indexed keywords

ANTIBODY; APTAMER; BORON; DENDRIMER; FOLIC ACID; GOLD; IBRITUMOMAB TIUXETAN; LIPOSOME; NANOPARTICLE; NANOTUBE; NUCLEIC ACID; RITUXIMAB; THIOREDOXIN; TRASTUZUMAB;

BIOTECHNOLOGICAL PRODUCTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; LIPOSOMAL DELIVERY; NANOTECHNOLOGY; PROTEIN TARGETING; SHORT SURVEY; VIRUS CAPSID;

MIRIDAE;

EID: 55049124399     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (53)

1. Gasparini G, Longo R, Torino F, Morabito A. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005;(16 Suppl 4):iv28-36.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
4. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
5. Ramalingam S, Belani CP. Role of bevacizumab for the treatment of non-small-cell lung cancer. Future Oncol 2007;3:131-9.
6. Eichele K, Ramer R, Hinz B. Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 2008;27:3032-44.
7. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:303-10.
8. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP et al. Epigenetic silencing of tumour suppressor gene p 15 by its antisense RNA. Nature 2008;451:202-6.
9. Huynh T, Walchli S, Sioud M. Transcriptional targeting of small interfering RNAs into cancer cells. Biochem Biophys Res Commun 2006;350:854-9.
10. Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008;5:309-19.
11. Wu J, Liu Q, Lee RJ. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 2006;316:148-53.
12. Gaber MH. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J Biochem Mol Biol Biophys 2002;6:309-14.
13. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233:134-44.
14. Choi Y, Thomas T, Kotlyar A, Islam MT, Baker JR, Jr. Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chem Biol 2005;12:35-43.
15. Shukla S, Wu G, Chatterjee M, Yang W, Sekido M, Diop LA et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem 2003;14:158-67.
16. Ballauff M, Likos CN. Dendrimers in solution: insight from theory and simulation. Angew Chem Int Ed Engl 2004;43:2998-3020.
17. Mecke A, Lee I, Baker JR, Jr., Holl MM, Orr BG. Deformability of poly(amidoamine) dendrimers. Eur Phys J E Soft Matter 2004;14:7-16.
18. Baek MG, Roy R. Synthesis and protein binding properties of T-antigen containing GlycoPAMAM dendrimers. Bioorg Med Chem 2002; 10: 11-7.
19. Abdelmoez W, Yasuda M, Ogino, H, Ishimi K, Ishikawa H. Synthesis of new polymer-bound adenine nucleotides using starburst PAMAM dendrimers. Biotechnol Prog 2002;18:706-12.
20. Myc A, Patri AK, Baker JR, Jr. Dendrimer-based BH3 conjugate that targets human carcinoma cells. Biomacromolecules 2007;8:2986-9.
21. Destito G, Yeh R, Rae CS, Finn MG, Manchester M. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol 2007;14:1152-62.
22. Caspar DLD, Klug A. Physical principles in the construction of regular viruses. Cold Spring Harbor Symposia on quantitative biology 1962;XXVII:1-24.
23. Wang Q, Kaltgrad E, Lin T, Johnson JE, Finn MG. Natural supramolecular building blocks. Wild-type cowpea mosaic virus. Chem Biol 2002;9:805-11.
24. Kam NW, O'Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A 2005;102:11600-5.
25. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem 2006;17:603-9.
26. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 2004;95:613-26.
27. Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci 2007;32:159-68.
28. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenyl-carbonyl groups. Biochim Biophys Acta 2001;1511:397-411.
29. Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Semin Oncol 2005;32(1 Suppl 1):S36-43.
30. Hsu ER, Anslyn EV, Dharmawardhane S, Alizadeh-Naderi R, Aaron JS, Sokolov KV et al. A far-red fluorescent contrast agent to image epidermal growth factor receptor expression. Photochem Photobiol 2004;79:272-9.
31. Nobs L, Buchegger F, Gurny R, Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 2006;17:139-45.
32. Welsher K, Liu Z, Daranciang D, Dai H. Selective probing and imaging of cells with single walled carbon nanotubes as near-infrared fluorescent molecules. Nano Lett 2008;8:586-90.
33. Davis JH, Szostak JW. Isolation of high-affinity GTP aptamers from partially structured RNA libraries. Proc Natl Acad Sci U S A 2002;99:11616-21.
34. McNamara JO, 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-15.
35. Cho S, Kim JE, Lee BR, Kim JH, Kim BG. Bis-aptazyme sensors for hepatitis C virus replicase and helicase without blank signal. Nucleic Acids Research 2005;33:e177.
36. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-72.
37. Whitson KB, Beechem JM, Beth AH, Staros JV. Preparation and characterization of Alexa Fluor 594-labeled epidermal growth factor for fluorescence resonance energy transfer studies: application to be epidermal growth factor receptor. Anal Biochem 2004;324:227-36.
38. Nordberg E, Friedman M, Gostring L, Adams GP, Brismar H, Nilsson FY et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 2007;34:609-18.
39. Mortensen MW, Sorensen PG, Bjorkdahl O, Jensen MR, Gundersen HJ, Bjornholm T. Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy. Appl Radiat Isot 2006;64:315-24.
40. Mortensen MW, Bjorkdahl O, Sorensen PG, Hansen T, Jensen MR, Gundersen HJ et al. Functionalization and cellular uptake of boron carbide nanoparticles. The first step toward T cell-guided boron neutron capture therapy. Bioconjug Chem 2006;17:284-90.
41. Wu P, Malkoch M, Hunt JN, Vestberg R, Kaltgrad E, Finn MG et al. Multivalent, bifunctional dendrimers prepared by click chemistry. Chem Commun (Camb) 2005:5775-7.
42. Seeman NC. DNA enables nanoscale control of the structure of matter. Q Rev Biophys 2005;38:363-71.
43. Smith SS, Niu L, Baker DJ, Wendel JA, Kane SE, Joy DS. Nucleoprotein-based nanoscale assembly. Proc Natl Acad Sci U S A 1997;94:2162-7.
44. Smith SS. A self-assembling nanoscale camshaft: implications for nanoscale materials and devices constructed from proteins and nucleic acids. Nano Letters (India) 2001;1:51-6.
45. Clark J, Shevchuk T, Kho MR, Smith SS. Methods for the design and analysis of oligodeoxynucleotide-based DNA (cytosine-5) methyl-transferase inhibitors. Anal Biochem 2003;321:50-64.
46. Singer EM, Smith SS. Nucleoprotein assemblies for cellular biomarker detection. Nano Lett 2006;6:1184-9.
47. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-91.
48. Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H et al. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 1991;68:1583-91.
49. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio, G et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 2000;24:53-60.
50. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 1992;69:2091-7.
51. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E et al. Thioredoxin, a putative oncogene product, is over-expressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000;31:475-81.
52. Matsutani Y, Yamauchi A, Takahashi R, Ueno M, Yoshikawa K, Honda K et al. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 2001;7:3430-6.
53. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.